Industry: Healthcare Providers
Study Type: FibroScan GO in SPAIN
Target Audience: Gastroenterologist & Endocrinologist
Geography: Spain
Length of Interview: 25 minutes
Background & Primary Goals
- The study’s main topic was a new FibroScan platform intended for the office market, where capital equipment purchases are not necessary.
- For calculating the proportion of individuals with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) who have received a cardiometabolic illness diagnosis.
- As well, to accurately predict the number of people with NAFLD/NASH who will be identified by doctors and/or treated in the next five years.
- For properly comprehending the invasive and/or noninvasive techniques used to diagnose individuals with NASH/NAFLD. And does insurance cover the cost of a fibroscan procedure.
Methodology & Approach
- Through online surveys, a total of 85 doctors were questioned, of whom 50 were gastroenterologists and 35 were endocrinologists. Gastroenterologists and endocrinologists from Spain who worked in settings including doctor’s offices, private hospitals, and clinics and had been in practice for more than two years made up the targeted audience.
- The doctors were presented with a speculative product called Fibroscan Go and asked for their opinions on the cost, including whether they would be willing to adopt the system if it were offered at a particular price and under a particular set of conditions, such as the total number of tests available each quarter.
- By offering them a specific price, we assessed whether it reflected a realistic price that is already widespread in the market. If it didn’t, we then asked what the true cost of a fibroscan machine might be with a view to elicit interest from various care settings.
Conclusion
- After the research was completed, we were able to draw conclusions regarding the prevalence of various liver diseases and the key diagnostic techniques. We also received a summary of the Spanish healthcare facilities’ EMR/HIS vendors.
- We did manage to estimate the median cost that can be applied to the product to make it desirable in the market and the specifications that need to be infused with it to cater to excellent service.
- After examining the data, we learned that the main techniques for determining whether a person has NASH/NAFLD include blood testing, imaging tests, and liver biopsy. In addition, among adult patients with NAFLD, more than 25% of individuals had cardiovascular metabolic problems.